Ginkgo Bioworks Holdings Total Liabilities
Ginkgo Bioworks Holdings total liabilities. Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has total liabilities worth $569.76 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DNA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ginkgo Bioworks Holdings (2019–2025)
Total liabilities of Ginkgo Bioworks Holdings from 2019 to 2025. This chart illustrates how Ginkgo Bioworks Holdings's total liabilities have evolved over time, based on quarterly financial data. Explore Ginkgo Bioworks Holdings strategic investment ratio to see how much of total assets are deployed in long-term investments.
Ginkgo Bioworks Holdings Competitors by Total Liabilities
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marcus Corporation
NYSE:MCS
|
USA | $550.89 Million |
|
Djerriwarrh Investments Ltd
AU:DJW
|
Australia | AU$69.24 Million |
|
Sido Muncul PT
JK:SIDO
|
Indonesia | Rp265.52 Billion |
|
Groupe CRIT SA
PA:CEN
|
France | €875.15 Million |
|
Firan Technology Group Corporation
TO:FTG
|
Canada | CA$70.91 Million |
|
Gansu Dunhuang Seed Co Ltd
SHG:600354
|
China | CN¥858.53 Million |
|
Zheshang Development Group Co Ltd
SHE:000906
|
China | CN¥48.49 Billion |
|
Actblue Co Ltd
SHE:300816
|
China | CN¥1.91 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Ginkgo Bioworks Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ginkgo Bioworks Holdings asset portfolio.
Liquidity & Leverage Metrics
Ginkgo Bioworks Holdings Total Liabilities Ratios Explained
Ginkgo Bioworks Holdings total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ginkgo Bioworks Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual total liabilities of Ginkgo Bioworks Holdings from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $611.11 Million | -7.60% |
| 2024-12-31 | $661.39 Million | +16.40% |
| 2023-12-31 | $568.19 Million | -29.25% |
| 2022-12-31 | $803.04 Million | +59.46% |
| 2021-12-31 | $503.61 Million | +145.54% |
| 2020-12-31 | $205.10 Million | +4.93% |
| 2019-12-31 | $195.47 Million | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more